Table 1.

Clinical characteristics of study participants.

Variables
Sex (male, %)	53 [10.7]
Age at diagnosis (years old)	58.3 [11.2]
Age at participation (years old)	66.0 [9.9]
Follow-up period (years)	6.2 [1.9–12.4]
AST (U/L)	27 [22–34]
ALT (U/L)	19 [14–26]
Alkaline phosphatase (xULN *)	0.83 [0.65–1.06]
≥1.50 (n, %)	37 [8.1]
Bilirubin (mg/dL)	0.62 [0.5–0.8]
≥2.0 mg/dL (n, %)	13 [2.8]
Albumin (g/dL)	4.1 [3.9–4.3]
≤3.5 g/dL (n, %)	33 [7.6]
Clinical events (present, %)	49 [11.8]
Use of UDCA (yes, %)	384 [88.3]
Use of bezafibrate (yes, %)	100 [23.0]

Continuous variables are shown as mean [standard deviation] if they are normally distributed and as median [interquartile range] if not.

^*2ULN, upper limit of normal.